269 related articles for article (PubMed ID: 22122766)
21. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
25. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase.
Gunnia UB; Amenta PS; Seibold JR; Thomas TJ
Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204
[TBL] [Abstract][Full Text] [Related]
27. Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.
Meyskens FL; Emerson SS; Pelot D; Meshkinpour H; Shassetz LR; Einspahr J; Alberts DS; Gerner EW
J Natl Cancer Inst; 1994 Aug; 86(15):1122-30. PubMed ID: 8028034
[TBL] [Abstract][Full Text] [Related]
28. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
29. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
[TBL] [Abstract][Full Text] [Related]
30. Difluoromethylornithine in cancer: new advances.
Alexiou GA; Lianos GD; Ragos V; Galani V; Kyritsis AP
Future Oncol; 2017 Apr; 13(9):809-819. PubMed ID: 28125906
[TBL] [Abstract][Full Text] [Related]
31. Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer.
Meyskens FL; Gerner EW
J Cell Biochem Suppl; 1995; 22():126-31. PubMed ID: 8538189
[TBL] [Abstract][Full Text] [Related]
32. Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW; Meyskens FL; Goldschmid S; Lance P; Pelot D
Amino Acids; 2007 Aug; 33(2):189-95. PubMed ID: 17396214
[TBL] [Abstract][Full Text] [Related]
33. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
Arbeit JM; Riley RR; Huey B; Porter C; Kelloff G; Lubet R; Ward JM; Pinkel D
Cancer Res; 1999 Aug; 59(15):3610-20. PubMed ID: 10446971
[TBL] [Abstract][Full Text] [Related]
34. Individual and combined effects of alpha-difluoromethylornithine and ovariectomy on the growth and polyamine milieu of experimental breast cancer in rats.
Manni A; Badger B; Glikman P; Bartholomew M; Santner S; Demers L
Cancer Res; 1989 Jul; 49(13):3529-34. PubMed ID: 2499419
[TBL] [Abstract][Full Text] [Related]
35. Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Einspahr JG; Nelson MA; Saboda K; Warneke J; Bowden GT; Alberts DS
Clin Cancer Res; 2002 Jan; 8(1):149-55. PubMed ID: 11801552
[TBL] [Abstract][Full Text] [Related]
36. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.
Merali S; Clarkson AB
Antimicrob Agents Chemother; 1996 Apr; 40(4):973-8. PubMed ID: 8849262
[TBL] [Abstract][Full Text] [Related]
37. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
[TBL] [Abstract][Full Text] [Related]
38. COX-2 expression in adenoma: an imperfect marker for chemoprevention.
Chan AT
Gut; 2010 May; 59(5):568-9. PubMed ID: 20427388
[No Abstract] [Full Text] [Related]
39. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and dietary agents for colorectal cancer chemoprevention: effects on polyamine metabolism (review).
Linsalata M; Orlando A; Russo F
Int J Oncol; 2014 Nov; 45(5):1802-12. PubMed ID: 25119812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
